Get the Stockscreener App
1.09
6.86%
0.07
Pre-market:
1.10
0.01
+0.92%
Onconetix Inc stock is traded at $1.09, with a volume of 437.48K.
It is up +6.86% in the last 24 hours and down -70.86% over the past month.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
See More
Previous Close:
$1.02
Open:
$1.06
24h Volume:
437.48K
Relative Volume:
0.40
Market Cap:
$4.02M
Revenue:
$735.20K
Net Income/Loss:
$-9.70M
P/E Ratio:
-0.0025
EPS:
-435.729
Net Cash Flow:
$-9.80M
1W Performance:
+7.92%
1M Performance:
-70.86%
6M Performance:
-98.89%
1Y Performance:
-99.54%
1-Day Range:
$0.9903
$1.1495
1-Week Range:
$0.9242
$1.1495
52-Week Range:
$0.911
$270.00
Onconetix Inc Stock (ONCO) Company Profile
Name
Onconetix Inc
Sector
Industry
Phone
513-620-4101
Address
201 E. FIFTH STREET, CINCINNATI
Compare ONCO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCO
Onconetix Inc
|
1.09 | 4.02M | 735.20K | -9.70M | -9.80M | -435.73 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Onconetix Inc Stock (ONCO) Latest News
Why Is Onco Micro-Cap Stock Surging 50% In Premarket? - Stocktwits
ONCO News | ONCONETIX INC (NASDAQ:ONCO) - ChartMill
Onconetix Company Profile & Introduction - Moomoo
OnconetixRegisters Up To 100 Million Shares For Resale By Keystone Capital PartnersSEC Filing - TradingView
ONCO Stock Price, Quote & Chart - ChartMill
Onconetix (ONCO) files S-1 for 100M-share Keystone equity line amid going-concern risks - Stock Titan
Onconetix approves 1-for-10 reverse stock split effective May 21 - Investing.com UK
Humanoid robot maker Realbotix posts $442K income, plans Nasdaq listing - Stock Titan
ONCO - Finviz
Number of shareholders of Onconetix Inc – FWB:J4T - TradingView
Number of shareholders of Onconetix Inc – GETTEX:A42ANX - TradingView
Pretax income of Onconetix Inc – GETTEX:A42ANX - TradingView
Onconetix Inc (ONCO) Stock Price, Quote, News & History - Benzinga
Onconetix reverse split 10-to-1, aimed at Nasdaq $1 bid rule - Stock Titan
Onconetix Sets 1-for-10 Reverse Stock Split Effective - TipRanks
Onconetix (ONCO) enacts 1-for-10 reverse split to support Nasdaq listing - Stock Titan
What's going on in today's session - ChartMill
Which stocks are most active on Tuesday? - ChartMill
Onconetix approves 1-for-10 reverse stock split effective May 21 By Investing.com - Investing.com Australia
Let's take a look at the stocks that are in motion in today's session. - ChartMill
Realbotix Provides Update on Nasdaq Listing - Investing News Network
Onconetix, Inc. announces 1-for-10 reverse stock split - marketscreener.com
Onconetix: Split Intended to Enable Co to Maintain Compliance With Minimum Bid Price Requirement of $1/Shr of Common Stk for Continued Listing on Nasdaq Cap Market >ONCO - Moomoo
Realbotix provides update on Nasdaq listing - marketscreener.com
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split - GlobeNewswire
Onconetix (ONCO) stock surges over 23% overnight: Why is it moving? - MSN
Onconetix shares jump 23.65% after clinical study boosts confidence in prostate cancer test Proclarix. - Pluang
Onconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving? - Benzinga
Stay updated with the stocks that are on the move in today's after-hours session. - ChartMill
Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed ... - Post Register
Onconetix Advances Proclarix Clinical Validation and Market Expansion - TipRanks
Onconetix (ONCO) highlights new Proclarix studies and U.S. PRIME trial - Stock Titan
Onconetix Reports Q1 2026 Progress: Proclarix® Validated in Peer-Reviewed Studies, U.S. PRIME Study Launched, and European Expansion Continues 1 - Minichart
Onconetix reports Proclarix peer-reviewed data and launches U.S. PRIME validation study with Labcorp - TradingView
Onconetix, Inc. Q1 2026 Financial Report: Key Risks, Market Strategies, and Forward-Looking Statements - Minichart
Onconetix's Proclarix advances with new studies and U.S. validation study launch, expanding in Europe. - Pluang
Onconetix reports Q1 progress for prostate cancer test Proclarix By Investing.com - Investing.com India
ONCO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Onconetix Reports Two Proclarix Publications and U.S. Validation Study in Q1 2026 - geneonline.com
Onconetix reports Q1 progress for prostate cancer test Proclarix - Investing.com
Onconetix Inc. Reports New Clinical Data Supporting Proclarix® in Reducing Overdiagnosis and Launches PRIME Study with Labcorp - Quiver Quantitative
Blood test aims to cut unnecessary prostate biopsies, now in U.S. study - Stock Titan
Onconetix Reports Q1 2026 Progress at Proteomedix AG, - GlobeNewswire
Onconetix, Inc. 1Q 2026: Revenue $21.46K, EPS ($6.71) — 10-Q Summary - TradingView
Onconetix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Onconetix (NASDAQ: ONCO) posts Q1 loss, warns on going concern amid Realbotix deal - Stock Titan
Onconetix, Inc. (ONCO) Eps Diluted (TTM) - Zacks Investment Research
How to Buy Onconetix (ONCO) Stock in Canada - Moomoo
[EFFECT] Onconetix, Inc. SEC Filing - Stock Titan
TradingKey - TradingKey
Onconetix (ONCO) registers 25M shares for resale under Keystone ELOC - Stock Titan
Onconetix Inc Stock (ONCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):